REFERENCES
1. Zhang M, Liu Q, Meng H, et al. Ischemia-reperfusion injury: molecular mechanisms and therapeutic targets. Sig Transduct Target Ther. 2024;9:12.
2. Soares ROS, Losada DM, Jordani MC, Évora P, Castro-E-Silva O. Ischemia/Reperfusion injury revisited: an overview of the latest pharmacological strategies. Int J Mol Sci. 2019;20:5034.
3. Nieuwenhuijs-Moeke GJ, Pischke SE, Berger SP, et al. Ischemia and reperfusion injury in kidney transplantation: relevant mechanisms in injury and repair. J Clin Med. 2020;9:253.
4. Goncharov RG, Sharapov MG. Ischemia-reperfusion injury: molecular mechanisms of pathogenesis and methods of their correction. Mol Biol. 2023;57:1143-64.
5. Wu M, Yiang G, Liao W, et al. Current mechanistic concepts in ischemia and reperfusion injury. Cell Physiol Biochem. 2018;46:1650-67.
6. Xin W, Qin Y, Lei P, Zhang J, Yang X, Wang Z. From cerebral ischemia towards myocardial, renal, and hepatic ischemia: exosomal miRNAs as a general concept of intercellular communication in ischemia-reperfusion injury. Mol Ther Nucl Acids. 2022;29:900-22.
7. Deng J, Liu Q, Ye L, et al. The Janus face of mitophagy in myocardial ischemia/reperfusion injury and recovery. Biomed Pharmacother. 2024;173:116337.
8. He S, Liu CY, Ren CH, Zhao H, Zhang XX. Immunological landscape of retinal ischemia-reperfusion injury: insights into resident and peripheral immune cell responses. Aging Dis. 2025;16:115-36.
9. Jurcau A, Simion A. Neuroinflammation in cerebral ischemia and ischemia/reperfusion injuries: from pathophysiology to therapeutic strategies. Int J Mol Sci. 2021;23:14.
10. Pefanis A, Ierino FL, Murphy JM, Cowan PJ. Regulated necrosis in kidney ischemia-reperfusion injury. Kidney Int. 2019;96:291-301.
11. Lu K, Zhu X, Li Y, Gu N. Progress in the preparation of Prussian blue-based nanomaterials for biomedical applications. J Mater Chem B. 2023;11:5272-300.
12. Qin Z, Li Y, Gu N. Progress in applications of Prussian blue nanoparticles in biomedicine. Adv Healthc Mater. 2018;7:1800347.
13. Zhang W, Hu S, Yin J, et al. Prussian blue nanoparticles as multienzyme mimetics and reactive oxygen species scavengers. J Am Chem Soc. 2016;138:5860-5.
14. He H, Long M, Duan Y, Gu N. Prussian blue nanozymes: progress, challenges, and opportunities. Nanoscale. 2023;15:12818-39.
15. Wang Y, Liang Z, Liang Z, Lv W, Chen M, Zhao Y. Advancements of Prussian blue-based nanoplatforms in biomedical fields: progress and perspectives. J Controlled Release. 2022;351:752-78.
16. Wang S, Li R, Shi X, et al. Sequential targeted nanomedicine MPC treats cerebral ischemia-reperfusion injury via neuronal microenvironment reprogramming. Chem Eng J. 2025;524:169755.
17. Long M, Wang L, Kang L, et al. Prussian blue nanozyme featuring enhanced superoxide dismutase-like activity for myocardial ischemia reperfusion injury treatment. ACS Nano. 2025;19:4561-81.
18. Huang Y, Xu Q, Zhang J, et al. Prussian blue scavenger ameliorates hepatic ischemia-reperfusion injury by inhibiting inflammation and reducing oxidative stress. Front Immunol. 2022;13:891351.
19. Wang Y, Fu H, Huang B, et al. Hollow mesoporous Prussian blue nanoenzymes as Rapamycin carrier for targeted treatment of ischemia/reperfusion-induced acute kidney injury through pro-mitophagy and oxidative stress alleviation. Chem Eng J. 2024;497:155684.
20. Hou R, Lu T, Gao W, et al. Prussian blue nanozyme promotes the survival rate of skin flaps by maintaining a normal microenvironment. ACS Nano. 2022;16:9559-71.
21. Peserico D, Stranieri C, Garbin U, et al. Ezetimibe prevents ischemia/reperfusion-induced oxidative stress and up-regulates Nrf2/ARE and UPR signaling pathways. Antioxidants. 2020;9:349.
22. Dugbartey GJ. Cellular and molecular mechanisms of cell damage and cell death in ischemia-reperfusion injury in organ transplantation. Mol Biol Rep. 2024;51:473.
23. Güler MC, Tanyeli A, Ekinci Akdemir FN, et al. An overview of ischemia-reperfusion injury: review on oxidative stress and inflammatory response. Eurasian J Med. 2023;54:S62-5.
24. Eltzschig HK, Eckle T. Ischemia and reperfusion—from mechanism to translation. Nat Med. 2011;17:1391-401.
25. Malkov MI, Lee CT, Taylor CT. Regulation of the hypoxia-inducible factor (HIF) by pro-inflammatory cytokines. Cells. 2021;10:2340.
26. Halladin NL. Oxidative and inflammatory biomarkers of ischemia and reperfusion injuries. Dan Med J. 2015;62:1-22.
27. Wu L, Xiong X, Wu X, et al. Targeting oxidative stress and inflammation to prevent ischemia-reperfusion injury. Front Mol Neurosci. 2020;13:28.
28. Peterson JM, Smith TA, Rock EP, Magnani JL. Selectins in biology and human disease: opportunity in E-selectin antagonism. Cureus. 2024;16:1-24.
29. Lv W, Liu Y, Li S, et al. Nano drug delivery system based on natural cells and derivatives for ischemic stroke treatment. Chin Med J. 2025;138:1945-60.
30. Dri E, Lampas E, Lazaros G, et al. Inflammatory mediators of endothelial dysfunction. Life. 2023;13:1420.
31. Puhl S, Steffens S. Neutrophils in post-myocardial infarction inflammation: damage vs. resolution? Front Cardiovasc Med. 2019;6:25.
32. Schofield ZV, Woodruff TM, Halai R, Wu MC, Cooper MA. Neutrophils - A key component of ischemia-reperfusion injury. Shock. 2013;40:463-70.
33. Duan W, Wang X, Ma Y, et al. Therapeutic strategies targeting the NLRP3‑mediated inflammatory response and pyroptosis in cerebral ischemia/reperfusion injury (Review). Mol Med Rep. 2024;29:46.
34. Gorsuch WB, Chrysanthou E, Schwaeble WJ, Stahl GL. The complement system in ischemia-reperfusion injuries. Immunobiology. 2012;217:1026-33.
35. De Oliveira THC, Gonçalves GKN. Complement system: a key player in hepatic ischemia-reperfusion injury. Biochem Biophys Res Commun. 2025;783:152580.
36. Hou Z, Brenner JS. Developing targeted antioxidant nanomedicines for ischemic penumbra: Novel strategies in treating brain ischemia-reperfusion injury. Redox Biol. 2024;73:103185.
37. Agbadua OG, Kúsz N, Berkecz R, Gáti T, Tóth G, Hunyadi A. Oxidized resveratrol metabolites as potent antioxidants and xanthine oxidase inhibitors. Antioxidants. 2022;11:1832.
38. Hou L, Zhao M, Huang C, He Q, Zhang L, Zhang J. Alternative oxidase gene induced by nitric oxide is involved in the regulation of ROS and enhances the resistance of Pleurotus ostreatus to heat stress. Microb Cell Fact. 2021;20:137.
39. He P, Talukder MAH, Gao F. Oxidative stress and microvessel barrier dysfunction. Front Physiol. 2020;11:472.
40. Neri M, Fineschi V, Paolo M, et al. Cardiac oxidative stress and inflammatory cytokines response after myocardial infarction. Curr Vasc Pharmacol. 2015;13:26-36.
41. Allowitz K, Taylor J, Harames K, Yoo J, Baloch O, Ramana KV. Oxidative stress-mediated lipid peroxidation-derived lipid aldehydes in the pathophysiology of neurodegenerative diseases. Curr Neuropharmacol. 2025;23:671-85.
42. Ambroz A, Klema J, Rossnerova A, et al. Associations of environmental pollution with pro-oxidant, antioxidant and inflammatory markers in pregnant mothers and newborns. Front Toxicol. 2025;7:1572486.
43. Rocco E, Grimaldi MC, Maino A, et al. Advances and challenges in biomarkers use for coronary microvascular dysfunction: from bench to clinical practice. J Clin Med. 2022;11:2055.
44. He H, Han Q, Wang S, et al. Design of a multifunctional nanozyme for resolving the proinflammatory plaque microenvironment and attenuating atherosclerosis. ACS Nano. 2023;17:14555-71.
45. Bai H, Wang T, Kong F, et al. CXCR4 and CD44 dual-targeted Prussian blue nanosystem with daunorubicin loaded for acute myeloid leukemia therapy. Chem Eng J. 2021;405:126891.
46. Ding X, Hu Y, Feng X, et al. Enhanced blood‐brain barrier penetrability of BACE1 SiRNA‐loaded prussian blue nanocomplexes for Alzheimer's disease synergy therapy. Exploration. 2025;5:e20230178.
47. Li X, Qiu C, Yang F, Li X, Fang Y, Yang Y. Protective effects of Prussian blue nanozyme against sepsis-induced acute lung injury by activating HO-1. Eur J Pharmacol. 2024;968:176354.
48. Wei W, Wang Y, Sun G, Chen Z, Zhang S. Prussian blue nanoparticles mitigate inflammatory osteolysis by reducing oxidative stress and enhancing endogenous antioxidant systems. Colloids Surf B Biointerfaces. 2025;254:114806.
49. Bai H, Kong F, Feng K, et al. Prussian blue nanozymes prevent anthracycline-induced liver injury by attenuating oxidative stress and regulating inflammation. ACS Appl Mater Interfaces. 2021;13:42382-95.
50. Feng Q, Xu H, Pan X, et al. Antioxidation and anti-inflammatory activity of Prussian blue nanozymes to alleviate acetaminophen-induced acute liver injury. ACS Appl Nano Mater. 2023;6:8468-81.
51. Li D, Liu M, Li W, et al. Synthesis of Prussian blue nanoparticles and their antibacterial, antiinflammation and antitumor applications. Pharmaceuticals. 2022;15:769.
52. Ramos-González E, Bitzer-Quintero O, Ortiz G, Hernández-Cruz J, Ramírez-Jirano L. Relationship between inflammation and oxidative stress and its effect on multiple sclerosis. Neurologia. 2024;39:292-301.
53. Zhang L, Ning X, Cui J, et al. Thermosensitive injectable in situ forming hydrogel incorporating anti-oxidative stress and anti-inflammatory nanoparticles for vital pulp therapy of pulpitis. Mater Today Biol. 2025;31:101482.
54. Ma X, Hao J, Wu J, Li Y, Cai X, Zheng Y. Prussian blue nanozyme as a pyroptosis inhibitor alleviates neurodegeneration. Adv Mater. 2022;34:2106723.
55. Yang J, Chen J, Liu Y, et al. Multifunctional Prussian blue nanozymes ameliorate tendinopathy via modulating tissue homeostasis. Mater Today Biol. 2025;34:102187.
56. Yang G, Li Q, Meng J, Dong H, Qin Z, Mou Y. Ultra-small Prussian blue nanodots scavenge reactive oxidative species and balance M1/M2 macrophages to mitigate colitis inflammation. Nanoscale. 2025;17:15402-12.
57. Qin Z, Li X, Wang P, et al. Ultrasmall Prussian blue nanozyme attenuates osteoarthritis by scavenging reactive oxygen species and regulating macrophage phenotype. Nano Lett. 2024;24:11697-705.
58. Ding H, Long M, Wu Y, et al. Subcellular distribution of Prussian blue nanozymes dictates enzymatic activity and macrophage polarization for effective colitis therapy. Biomaterials. 2026;325:123622.
59. Liu J, Sun J, Song Y, et al. Prussian blue nanozyme treatment of ischemic brain injury via reducing oxidative stress inhibits inflammation, suppresses apoptosis, and promotes neurological recovery. ACS Chem Neurosci. 2023;14:1535-46.
60. Zhang K, Tu M, Gao W, et al. Hollow Prussian blue nanozymes drive neuroprotection against ischemic stroke via attenuating oxidative stress, counteracting inflammation, and suppressing cell apoptosis. Nano Lett. 2019;19:2812-23.
61. Xiong T, Wang S, Shi X, et al. Biomimetic dynamic nanomedicine SrHCF: lattice self-reconstruction based on Fe2+ response to achieve synergistic “ferrous chelation-antioxidation-calcium antagonism-inflammation inhibition” quadruple treatment of CIRI. Bioact Mater. 2026;55:23-41.
62. Song Y, Wang L, Peng T, et al. Brain-targeting biomimetic nanozyme enhances neuroprotection in ischemic stroke by remodeling the neurovascular unit. J Controlled Release. 2025;382:113750.
63. Song J, Yang G, Song Y, et al. Neutrophil hitchhiking biomimetic nanozymes prime neuroprotective effects of ischemic stroke in a tailored “burning the bridges” manner. Adv Funct Mater. 2024;34:2315275.
64. Zhang Q, Li S, Chen H, et al. Reduction of oxidative stress and excitotoxicity by mesenchymal stem cell biomimetic co-delivery system for cerebral ischemia-reperfusion injury treatment. Small. 2024;20:2401045.
65. Liu Y, Zhou M, Xu M, et al. Reprogramming monocytes into M2 macrophages as living drug depots to enhance treatment of myocardial ischemia-reperfusion injury. J Controlled Release. 2024;374:639-52.
66. Shen P, Huang K, Zhang X, Qin M, Wang X, Fan Z. Neutrophil-mimicking Prussian blue nanozymes for synergistic targeted immuno-metabolic therapy of hepatic ischemia-reperfusion injury. J Nanobiotechnol. 2025;23:736.
67. Sahu A, Jeon J, Lee MS, Yang HS, Tae G. Nanozyme impregnated mesenchymal stem cells for hepatic ischemia-reperfusion injury alleviation. ACS Appl Mater Interfaces. 2021;13:25649-62.
68. Xiong X, Yin C, Tong A, et al. Dermal extracellular matrix gelatin delivering Prussian blue nanoparticles to relieve skin flap ischemia. Int J Biol Macromol. 2024;267:131361.
69. Yang L, Liu Y, Tao C, et al. Bionic nanovesicles sequentially treat flaps with different durations of ischemia by thrombolysis and prevention of ischemia-reperfusion injury. Mater Today Bio. 2025;31:101529.
70. Yang M, Liu B, Chen B, Shen Y, Liu G. Cerebral ischemia-reperfusion injury: mechanisms and promising therapies. Front Pharmacol. 2025;16:1613464.
71. Du B, Fu Q, Yang Q, et al. Different types of cell death and their interactions in myocardial ischemia-reperfusion injury. Cell Death Discov. 2025;11:87.
72. George J, Lu Y, Tsuchishima M, Tsutsumi M. Cellular and molecular mechanisms of hepatic ischemia-reperfusion injury: The role of oxidative stress and therapeutic approaches. Redox Biol. 2024;75:103258.
73. Chen Y, Yang L. Cellular senescence in renal ischemia-reperfusion injury. Chin Med J. 2025;138:1794-806.
74. Li C, Yu Y, Zhu S, et al. The emerging role of regulated cell death in ischemia and reperfusion-induced acute kidney injury: current evidence and future perspectives. Cell Death Discov. 2024;10:216.
75. Liu S, Xiong X, Chen L, et al. Targeting programmed cell death in flap ischemia/reperfusion injury. Biomolecules. 2025;15:911.
